IROKO Cardio International is a privately held global pharmaceutical company located in Geneva, Switzerland.
IROKO Cardio commercialises Aggrastat® in more than 80 countries worldwide directly and via its distributor partner network.
Aggrastat® (tirofiban) is a reversible GPIIBIIIA receptor inhibitor for use in acute coronary syndrome (ACS) patients.
IROKO Cardio helps healthcare professionals (HCPs) reduce Major Adverse Cardiac Events (MACE) in ACS patients through:
- The use of Aggrastat®
- A multi-lingual 24/7//365 medical information center
- Contemporary and relevant medical education tools
Aggrastat® is used to treat more than 250'000 patients annually and IROKO Cardio measures its business success in MACE prevented (approximately 18'000 MACE annually).
Aggrastat®'s efficacy and safety has been demonstrated in clinical trials involving more than 20'000 patients.
In 2010, Aggrastat® received EU regulatory approval for high dose bolus (HDB) use in high risk NSTE-ACS (non-ST elevation myocardial infarction) patients undergoing PCI (per-cutaneous coronary intervention) and its use has been endorsed in the 2011 ESC (European Society of Cardiology) NSTEMI treatment guidelines.
High risk ACS patients present an urgent medical challenge for HCPs in their quest to prevent myocardial infarction (MI) and preserve patient quality of life. Approximately 1.4 million patients suffer from ACS/MI in Europe annually.
IROKO Cardio has been founded to organize and support the commercial effort for Aggrastat.
In close cooperation with our worldwide distribution partners, we aim to provide state of the art customer services to the clinical community we serve.